Hagop Kantarjian – författare

Leukemia continues to offer the scientist a unique opportunity to gain new knowledge about the malignant transformation. As a result, this multi-authored volume, devoted to advances which have occurred over the last seven years, provides the reader with an important new understanding of leukemia, but perhaps even more important, predicts analogous, new developments in the other malignant diagnoses. In this respect, this volume represents the cutting edge of cancer research. This text is unique in that it includes in a single volume the leading contributors to their respective fields covering what the editors feel are the major advances in our knowledge of the biology and therapy of leukemia over the last seven years.

Leukemia is a malignant disease which continues to play a cutting edge role in the discovery of new basic knowledge about the malignant process and about the potential for controlling these malignant diseases. Molecular Genetics and Therapy of Leukemia presents contributions by leading investigators and scientific contributors to such topics as chromosome 16, chromosome 5, the BCL-2 gene, 11q23 breakpoint leukemias, the p-53 suppressor gene and oncogene, hematopoietic stem cells, cytokines, detection of minimal residual disease in acute lymphoblastic leukemia, autologous marrow transplantation, the retinoblastoma gene, allogeneic bone marrow transplant and chemotherapy of acute lymphoblastic leukemia.

Expert, hands-on guidance for the practicing oncologist—from the leader in the field of cancer management—completely updated to reflect the latest advances

A Doody's Core Title for 2023, 2024 & 2026! 

Comprehensive and authoritative, The MD Anderson Manual of Medical Oncology delivers everything you need to accurately diagnose and effectively treat a wide range of cancers—including leukemia, lymphoma, myeloma, lung and breast cancer, genitourinary carcinoma, melanoma, and sarcoma.

This unmatched resource emphasizes practical, actionable steps to cancer treatment, providing "to the point" recommendations, chapter summary boxes, tables, charts, expert opinion and patient education boxes, practice tips, cases, and prescriptive advice. The new format of this updated edition quickly guides you to the topic, the affiliated relevant chapter, new findings affecting clinical practice, and reference/evidence.

This fourth edition features:

NEW Q&A, cases, patient education information, and expert adviceExpanded coverage of immunotherapy treatment—written by the 2018 Nobel Prize-winner for immunologyAccess to continually updated online contentA comparative table with guidelines from the European Society of Medical Oncology and the American Society of Clinical OncologyAn emphasis on recent developments in precision medicine and immunotherapies

Plus important NEW chapters on:

Cord blood transplantHaploidentical cell transplantationCellular therapy in allogeneic hematopoietic cell transplantationPediatric cancersMolecular biomarkers and cancerImmune-oncologyTargeted therapies in cancerApplied biostatisticsOncocardiologyPulmonary complications of cancer associated thrombosis

Edited by experts from one of the world’s largest leukemia centers, this book provides information on the biology of the variety of leukemic disorders, up-to-date diagnostic testing and many new developments in therapy. Chapters covering new treatments present an outlook for the future and explain the rationale for ongoing clinical trials. Topics include: Targeted therapy, e.g. tyrosine kinase inhibitors (Flt3, Aurora kinase inhibitors, kit inhibitors, BCR-ABL inhibitors)Ras inhibitorsEpigenetic therapy (hypomethylaters and histone deacetylase inhibitors)Lenalidomide analogsNew chemotherapy drugs, e.g. clofarabine, cloretazine, sapacitabine, forodesineCombinations of chemotherapy with kinase inhibitors (e.g. ALL induction protocols in combination with dasatinib or imatinib)New monoclonal antibodies (lumiliximab, humaxCD20, anti-CD40)Thrombopoietic agentsLeukemias: Principles and Practice of Therapy Includes practical information to guide you in challenging situations, such as treatment of elderly patients, pregnancy, relapsed and refractory diseaseIncorporates chapters on supportive care and pharmacologic information about the most frequently used drugs in this area

Edited by experts from one of the world’s largest leukemia centers, this book provides information on the biology of the variety of leukemic disorders, up-to-date diagnostic testing and many new developments in therapy. Chapters covering new treatments present an outlook for the future and explain the rationale for ongoing clinical trials.

Topics include:

Targeted therapy, e.g. tyrosine kinase inhibitors (Flt3, Aurora kinase inhibitors, kit inhibitors, BCR-ABL inhibitors) Ras inhibitors Epigenetic therapy (hypomethylaters and histone deacetylase inhibitors) Lenalidomide analogs New chemotherapy drugs, e.g. clofarabine, cloretazine, sapacitabine, forodesine Combinations of chemotherapy with kinase inhibitors (e.g. ALL induction protocols in combination with dasatinib or imatinib) New monoclonal antibodies (lumiliximab, humaxCD20, anti-CD40) Thrombopoietic agents

Leukemias: Principles and Practice of Therapy

Includes practical information to guide you in challenging situations, such as treatment of elderly patients, pregnancy, relapsed and refractory disease Incorporates chapters on supportive care and pharmacologic information about the most frequently used drugs in this area

Edited by experts from one of the world’s largest leukemia centers, this book provides information on the biology of the variety of leukemic disorders, up-to-date diagnostic testing and many new developments in therapy. Chapters covering new treatments present an outlook for the future and explain the rationale for ongoing clinical trials.

Topics include:

Targeted therapy, e.g. tyrosine kinase inhibitors (Flt3, Aurora kinase inhibitors, kit inhibitors, BCR-ABL inhibitors) Ras inhibitors Epigenetic therapy (hypomethylaters and histone deacetylase inhibitors) Lenalidomide analogs New chemotherapy drugs, e.g. clofarabine, cloretazine, sapacitabine, forodesine Combinations of chemotherapy with kinase inhibitors (e.g. ALL induction protocols in combination with dasatinib or imatinib) New monoclonal antibodies (lumiliximab, humaxCD20, anti-CD40) Thrombopoietic agents

Leukemias: Principles and Practice of Therapy

Includes practical information to guide you in challenging situations, such as treatment of elderly patients, pregnancy, relapsed and refractory disease Incorporates chapters on supportive care and pharmacologic information about the most frequently used drugs in this area

Leukemia is a malignant disease which continues to play a cutting edge role in the discovery of new basic knowledge about the malignant process and about the potential for controlling these malignant diseases. Molecular Genetics and Therapy of Leukemia presents contributions by leading investigators and scientific contributors to such topics as chromosome 16, chromosome 5, the BCL-2 gene, 11q23 breakpoint leukemias, the p-53 suppressor gene and oncogene, hematopoietic stem cells, cytokines, detection of minimal residual disease in acute lymphoblastic leukemia, autologous marrow transplantation, the retinoblastoma gene, allogeneic bone marrow transplant and chemotherapy of acute lymphoblastic leukemia.

Leukemia continues to offer the scientist a unique opportunity to gain new knowledge about the malignant transformation. As a result, this multi-authored volume, devoted to advances which have occurred over the last seven years, provides the reader with an important new understanding of leukemia, but perhaps even more important, predicts analogous, new developments in the other malignant diagnoses. In this respect, this volume represents the cutting edge of cancer research. This text is unique in that it includes in a single volume the leading contributors to their respective fields covering what the editors feel are the major advances in our knowledge of the biology and therapy of leukemia over the last seven years.